2.43 USD
+0.04 (+1.67%)
ZY gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 82 industry peers in the Chemicals industry. While ZY seems to be doing ok healthwise, there are quite some concerns on its profitability. ZY does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- ZY had negative earnings in the past year.
- ZY had a negative operating cash flow in the past year.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -77.49% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | -1836.72% | ||
| PM (TTM) | -2508.94% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ZY does not have a ROIC to compare to the WACC, probably because it is not profitable.
- ZY has more shares outstanding than it did 1 year ago.
- Compared to 1 year ago, ZY has an improved debt to assets ratio.
2.2 Solvency
- ZY has an Altman-Z score of -4.65. This is a bad value and indicates that ZY is not financially healthy and even has some risk of bankruptcy.
- ZY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.65 |
ROIC/WACCN/A
WACC12.14%
2.3 Liquidity
- ZY has a Current Ratio of 4.59. This indicates that ZY is financially healthy and has no problem in meeting its short term obligations.
- A Quick Ratio of 4.47 indicates that ZY has no problem at all paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.59 | ||
| Quick Ratio | 4.47 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 53.02% over the past year.
- The Revenue for ZY has decreased by -22.23% in the past year. This is quite bad
EPS 1Y (TTM)53.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.08%
Revenue 1Y (TTM)-22.23%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-55.01%
3.2 Future
- The Earnings Per Share is expected to grow by 9.49% on average over the next years. This is quite good.
- Based on estimates for the next years, ZY will show a very strong growth in Revenue. The Revenue will grow by 36.42% on average per year.
EPS Next Y33.88%
EPS Next 2Y20.08%
EPS Next 3Y20.85%
EPS Next 5Y9.49%
Revenue Next Year-21.93%
Revenue Next 2Y16.02%
Revenue Next 3Y24.75%
Revenue Next 5Y36.42%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ZY. In the last year negative earnings were reported.
- Also next year ZY is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | -0.16 |
4.3 Compensation for Growth
- ZY's earnings are expected to grow with 20.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.08%
EPS Next 3Y20.85%
5. Dividend
5.1 Amount
- ZY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ZYMERGEN INC / ZY FAQ
What is the fundamental rating for ZY stock?
ChartMill assigns a fundamental rating of 3 / 10 to ZY.
What is the valuation status for ZY stock?
ChartMill assigns a valuation rating of 2 / 10 to ZYMERGEN INC (ZY). This can be considered as Overvalued.
Can you provide the profitability details for ZYMERGEN INC?
ZYMERGEN INC (ZY) has a profitability rating of 1 / 10.
How financially healthy is ZYMERGEN INC?
The financial health rating of ZYMERGEN INC (ZY) is 6 / 10.